Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ALRN

Aileron Therapeutics (ALRN) Stock Price, News & Analysis

Aileron Therapeutics logo

About Aileron Therapeutics Stock (NASDAQ:ALRN)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$1.75
$3.93
52-Week Range
N/A
Volume
63,385 shs
Average Volume
82,013 shs
Market Capitalization
$45.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive ALRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aileron Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ALRN Stock News Headlines

Aileron Therapeutics Rebrands As Rein Therapeutics
Silicon Valley Gold Rush
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free.
See More Headlines

ALRN Stock Analysis - Frequently Asked Questions

Aileron Therapeutics, Inc. (NASDAQ:ALRN) released its quarterly earnings data on Wednesday, August, 14th. The company reported ($0.45) earnings per share for the quarter, missing analysts' consensus estimates of ($0.25) by $0.20.

Aileron Therapeutics's stock reverse split before market open on Thursday, November 10th 2022.The 1-20 reverse split was announced on Thursday, November 10th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 10th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Aileron Therapeutics (ALRN) raised $61 million in an initial public offering (IPO) on Thursday, June 29th 2017. The company issued 3,800,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch and Jefferies served as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Aileron Therapeutics investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), NIO (NIO), AST SpaceMobile (ASTS), Virgin Galactic (SPCE) and Phunware (PHUN).

Company Calendar

Last Earnings
8/14/2024
Today
7/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ALRN
Fax
N/A
Employees
9
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$15.73 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$1.41 per share
Price / Book
N/A

Miscellaneous

Free Float
20,561,000
Market Cap
$45.72 million
Optionable
Not Optionable
Beta
2.24

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:ALRN) was last updated on 7/6/2025 by MarketBeat.com Staff
From Our Partners